目的 探讨保利尔胶囊联合非诺贝特治疗高脂血症的临床疗效。方法 选取2021年5月—2023年5月中国中医科学院广安门医院收治的98例高血脂症患者，按照随机数字法将患者分为对照组（49例）和治疗组（49例）。对照组随餐口服非诺贝特胶囊，0.2 g/次，1次/d。在对照组的基础上，治疗组口服保利尔胶囊，5粒/次，3次/d。两组患者治疗15 d。观察两组患者临床疗效，比较治疗前后两组患者症状改善时间，血清总胆固醇、瘦素、血沉、脂联素、白细胞介素-6（IL-6）、IL-1β、细胞间黏附分子-1（ICAM-1）和超氧化物歧化酶（SOD）水平，及不良反应情况。结果 治疗后，治疗组临床总有效率（97.96%）明显高于对照组（81.63%，P＜0.05）。治疗后，治疗组症状改善时间均明显早于对照组（P＜0.05）。治疗后，两组脂联素和SOD明显高于治疗前，而总胆固醇、瘦素、血沉、IL-6、IL-1β、ICAM-1水平均明显低于治疗前（P＜0.05），且治疗组这些血清因子水平明显好于对照组（P＜0.05）。治疗后，治疗组不良反应发生率（6.22%）明显低于对照组发生率（16.33%，P＜0.05）。结论 非诺贝特与保利尔胶囊协同治疗效果确切，对临床症状可以有效改善，能使高血脂有效调节，并减弱机体炎性反应状态。

Objective To explore the clinical effect of Baolile Capsules combined with fenofibrate in treatment of hyperlipidemia. Methods Patients (98 cases) with hyperlipidemia admitted to Guang’anmen Hospital of China Academy of Chinese Medical Sciences from May 2021 to May 2023 were selected and divided into control group (49 cases) and treatment group (49 cases) according to random number method. Patients in the control group were po administered with Fenofibrate Capsules, 0.2 g/time, once daily. Patients in the treatment group were po administered with Baolier Capsules on the basis of the control group, 5 grains/time, three times daily. Patients in two groups were treated for 15 d. After treatment, the clinical effect was evaluated, and the symptom relief times, the levels of total cholesterol, leptin, erythrocyte sedimentation rate, adiponectin, IL-6, IL-1β, ICAM-1, and SOD, and adverse reaction in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group (97.96%) was significantly higher than that of the control group (81.63%, P < 0.05). After treatment, the time of symptom improvement in the treatment group was significantly earlier than that in the control group (P < 0.05). After treatment, the levels of adiponectin and SOD in two groups were significantly higher than those before treatment, while the levels of total cholesterol, leptin, ESR, IL-6, IL-1β, and ICAM-1 were significantly lower than those before treatment (P < 0.05), and the levels of these serum factors in the treatment group were significantly better than those in the control group (P < 0.05). After treatment, the incidence of adverse events in the treatment group (6.22%) was significantly lower than that in the control group (16.33%, P < 0.05). Conclusion Baolier Capsules combined with fenofibrate are effective in the treatment of hyperlipidemia, which can effectively improve the clinical symptoms, regulate hyperlipidemia and weaken the inflammatory state.

R972